NGM lands $51M for preclinical diabetes work

NGM Biopharmaceuticals today announced it has closed the first tranche of a $51 million Series B round of financing with the help of Column Group, Tichenor Ventures, Prospect Venture Partners, Rho Ventures and other new and existing investors. The South San Francisco-based company, which was founded in 2008, also announced the appointment of McHenry Tichenor, Jr., managing member of Tichenor Ventures, to the NGM board of directors. He joins former Genentech CEO Art Levinson, who was named to NGM's board last October.

NGM has developed a drug discovery platform based on the company's observations of patient results following gastric bypass surgery. The company notes that people who undergo gastric bypass often experience immediate remission of diabetes, even before they've lost significant weight. Its gastrointestinal program is designed to understand and mimic the effects of bariatric
surgery-induced diabetes remission. Additionally, NGM has a portfolio of targets and factors that restore glucose balance in preclinical models of Type 2 diabetes.

- here's NGM's release

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.